Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2022 | $7.00 → $6.00 | Buy | HC Wainwright & Co. |
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)
HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously
HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously
Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50
10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)
425 - Arcadia Biosciences, Inc. (0001469443) (Subject)
8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. "We are very pleased with our performance for the second quarter of 2025," said T.J. Schaefer, CEO of Arcadia. "While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once aga
-- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has
DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register
-- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to
DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.
DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. "We are very pleased with our performance for the second quarter of 2025," said T.J. Schaefer, CEO of Arcadia. "While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once aga
-- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has
DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register
SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)
SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)
SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)